

## BIO-GENE APPOINTS NEW CHAIRMAN

---

Bio-Gene Technology Limited (ASX: BGT, **Bio-Gene** or the **Company**), an agtech development company enabling the next generation of novel insecticides, announces the appointment of Non-Executive Director Alex Ding as the new Chairman of the Board, effective 1 August 2023. He replaces Mr Robert Klupacs who on 12 May 2023 announced his intention to retire as Chairman and Non-Executive Director, effective 31 July, 2023.

Mr Alex Ding joined Bio-Gene as Non-Executive Director on 12 May, 2023. Mr Ding was previously a partner at two leading Australian law firms, and is a recognised expert in mergers and acquisitions, capital markets, and general corporate and governance law. He has advised many large ASX, LSE and US listed companies, foreign government-controlled entities and substantial private companies and funds on acquisitions, divestments, corporate finance transactions, joint venture arrangements, restructurings, corporate governance and disputes strategy. He has been named on The Best Lawyers in Australia™ list.

**Commenting on Mr Ding’s appointment, Bio-Gene CEO, Richard Jagger, said:**

“I am delighted to welcome Alex as the new Chairman of Bio-Gene’s Board. Alex’s commercial and financial expertise strengthens our commercial capability, crucial for Bio-Gene during this pivotal time as we develop and execute our strategy for growth. Alex will guide us to build on current commercial partnerships and ensure our unique proprietary technology advances in global crop protection and public health markets.”

Mr Robert Klupacs joined Bio-Gene in 2015 as CEO and lead the Company to IPO in 2017 before becoming a Non-Executive Director in January 2018. Robert became Chair of the Company in November 2019. Mr Klupacs has resigned due to significantly increasing commitments associated with his other roles.

**Commenting on Mr Klupacs’ retirement, Bio-Gene CEO, Richard Jagger, said:**

“On behalf of Bio-Gene, I sincerely thank Robert for his tireless efforts and guidance over the past eight years. Robert has been an integral part of Bio-Gene’s journey as we developed from a research-based start-up to a commercially viable listed company. First as CEO, then through his time on the board, and particularly as the Chair, Robert has been a vital member and we thank him for his service and wish him all the best on his much-deserved retirement.

Approved for release by the Board of Directors.

- ENDS -

**For further information, please contact:**

Bio-Gene Technology Limited:  
E: [bgt.info@bio-gene.com.au](mailto:bgt.info@bio-gene.com.au)

Adrian Mulcahy, Investor Relations  
E: [adrian.mulcahy@automicgroup.com.au](mailto:adrian.mulcahy@automicgroup.com.au)  
M: 0438 630 422

Tristan Everett, Media Relations  
E: [tristan.everett@automicgroup.com.au](mailto:tristan.everett@automicgroup.com.au)  
M: 0403 789 096

**About Bio-Gene Technology Ltd**

Bio-Gene is an Australian agtech company enabling the next generation of novel insecticides. Bio-Gene's novel platform technology is based on a naturally occurring class of chemicals known as beta-triketones. Beta-triketone compounds have demonstrated insecticidal activity (e.g., kill or knock down insects) via a novel mode of action in testing performed to date. This platform may provide multiple potential new solutions for insecticide manufacturers in applications across crop protection and storage, public health, animal health and consumer applications. The Company's aim is to develop and commercialise a broad portfolio of targeted insect control and management solutions.

**Flavocide™ and Qcide™** are trademarks of Bio-Gene Technology Limited.